Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High Following Analyst Upgrade
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) hit a new 52-week high during trading on Wednesday after BMO Capital Markets raised their price target on the stock from $16.00 to $17.00. BMO Capital Markets currently has a market perform rating on the stock. Halozyme Therapeutics traded as high as $18.01 and last traded at $17.72, with a volume of 184682 shares trading hands. The stock had previously closed at $16.77.
A number of other analysts have also commented on HALO. Barclays raised Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and cut their price target for the company from $17.00 to $16.00 in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday. ValuEngine lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective on the stock in a research note on Thursday, November 7th. Four investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $20.33.
Several institutional investors have recently bought and sold shares of the stock. Carillon Tower Advisers Inc. acquired a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $16,332,000. Eagle Asset Management Inc. acquired a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $23,894,000. SG Americas Securities LLC lifted its stake in shares of Halozyme Therapeutics by 23.4% in the third quarter. SG Americas Securities LLC now owns 10,482 shares of the biopharmaceutical company’s stock worth $163,000 after acquiring an additional 1,986 shares during the period. First Trust Advisors LP acquired a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $669,000. Finally, Synovus Financial Corp lifted its stake in shares of Halozyme Therapeutics by 4.2% in the third quarter. Synovus Financial Corp now owns 58,403 shares of the biopharmaceutical company’s stock worth $898,000 after acquiring an additional 2,375 shares during the period. 84.35% of the stock is currently owned by institutional investors.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.05). Halozyme Therapeutics had a negative net margin of 19.73% and a negative return on equity of 15.59%. The business had revenue of $46.20 million during the quarter, compared to analyst estimates of $54.96 million. During the same period last year, the firm posted ($0.19) earnings per share. Halozyme Therapeutics’s quarterly revenue was up 80.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post -0.31 EPS for the current fiscal year.
About Halozyme Therapeutics (NASDAQ:HALO)
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Read More: What does an inverted yield curve signify?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.